Saturday September 13th, 2014
Chestnut Conference Centre, University of Toronto
Giovanni Room • 89 Chestnut Street • Toronto, Ontario

Program Goals
✓ Improve clinical utilization of plasma, plasma protein products and recombinant proteins.
✓ Improve understanding of the coagulation process and how new plasma proteins and recombinants may potentially increase safety and efficacy.
✓ Improve understanding of methodologies available in the clinical coagulation laboratory.

7:30 – 8:20  Light Continental Breakfast & Registration

Welcome
8:20 – 8:25  Dr. Dana Devine, Canadian Blood Services and University of British Columbia, Vancouver
8:25 – 8:40  The World of Plasma In One Day
            Dr. Robert Skeate, Canadian Blood Services and University of Toronto, Toronto
            Including 5min Q&A

Session 1: Plasma Transfusion
Chair: Dr. Robert Skeate, Canadian Blood Services and University of Toronto, Toronto

8:40 – 9:25  Rethinking the Coagulation Cascade: From Plasma Proteins to the Role of Cells
            Dr. Maureen Hoffman, Duke University Medical Center, Durham, USA
            Including 10min Q&A

9:25 – 10:10  Plasma Transfusion: Continuing Controversies
              Dr. Walter H. Dzik, Massachusetts General Hospital, Boston, USA
              Including 10min Q&A

10:10 – 10:40  Coffee Break

10:40 – 11:10  Clinical Utilization of Plasma
               Dr. Alan Tinmouth, The Ottawa Hospital, Ottawa
               Including 5min Q&A

An event organized and sponsored by Canadian Blood Services Centre for Innovation
11:10 – 11:40 What Can We Learn from Animal Models of Coagulopathy and Bleeding?
Dr. William Sheffield, Canadian Blood Services and McMaster University, Hamilton
Including 5min Q&A

11:40 – 12:00 Forum Discussion: The Future of Plasma Transfusion
Dr. Walter H. Dzik, Massachusetts General Hospital, Boston, USA
Dr. Alan Tinmouth, The Ottawa Hospital, Ottawa
The audience will be invited to participate.

12:00 – 13:00 Networking Lunch (Terrace 3rd floor)

Session 2: Plasma Testing
Chair: Dr. William Sheffield, Canadian Blood Services and McMaster University, Hamilton
13:00 – 13:30 Plasma Testing in the Clinical Coagulation Laboratory: New Drugs, New Problems
Karen Moffat, Hamilton Regional Laboratory Medicine Program and McMaster University, Hamilton
Including 5min Q&A

Session 3: Plasma Fractionation & Plasma Protein Product Replacement
Chair: Dr. William Sheffield, Canadian Blood Services and McMaster University, Hamilton
13:30 – 14:00 Plasma Protein Products: Where do they come from?
Dr. Barbara Hannach, Canadian Blood Services, Toronto
Including 5min Q&A

14:00 – 14:15 Break

14:15 – 14:45 Clinical Experience with Prothrombin Complex Concentrates
Dr. Mark Blostein, Jewish General Hospital and McGill University, Montreal
Including 5min Q&A

14:45 – 15:30 The Arrival of Longer Lasting Recombinant Products
Dr. Steven Pipe, C.S. Mott Children’s Hospital and University of Michigan, Ann Arbor, USA
Including 10min Q&A

Meeting Wrap-up
15:30 – 15:45 Dr. William Sheffield, Canadian Blood Services and McMaster University, Hamilton
Upon completion of this program participants will be able to:

✓ Explain how plasma components and cells control coagulation;
✓ Explain how an inappropriate clotting process may cause diseases;
✓ Describe the current clinical indications for transfusing plasma and plasma protein products;
✓ Describe the clinical use of longer-lasting recombinant products for the care of hemophiliac patients;
✓ Apply findings from clinical studies to the clinical use of plasma and plasma protein products;
✓ Optimize utilization of plasma and plasma proteins through appropriate use of coagulation tests;
✓ List the current plasma products, plasma protein products and recombinant proteins available in Canada;
✓ List the various sources of plasma for fractionation and describe the fractionation process for plasma-derived factors;
✓ Describe how plasma products are brought to market in Canada;
✓ Explain the needs for future research in the area of plasma therapy;
✓ Describe available animal models of coagulopathy and bleeding;
✓ Describe why fibrinogen is likely a more important component than FVIII in transfused plasma;
✓ Contribute to discussions concerning the continuing controversies in plasma and plasma product transfusion.

This program was developed in collaboration with:

Continuing Professional Development (CPD), Faculty of Medicine, University of Toronto, is fully accredited by the Committee on Accreditation of Continuing Medical Education (CACME), a subcommittee of the Committee on Accreditation of Canadian Medical Schools (CACMS). This standard allows CPD to assign credits for educational activities based on the criteria established by The College of Family Physicians of Canada, and the Royal College of Physicians and Surgeons of Canada.

As a result of a reciprocal agreement between the Royal College of Physicians and Surgeons of Canada, The American Medical Association, and The European Union for Medical Specialists, CPD is permitted to assign respective credits.
Planning Committee Membership

Dr. William Sheffield (Co-chair), Associate Director and Senior Scientist, Centre for Innovation, Canadian Blood Services & Professor, McMaster University

Dr. Kathryn Webert (Co-chair), Medical Director, Medical Services and Utilization, Canadian Blood Services & Associate Professor, McMaster University

Dr. Robert Skeate (Course Director), Associate Medical Director, Medical Services and Utilization, Canadian Blood Services & Assistant Professor, University of Toronto

Dr. Donald Branch, Scientist, Centre for Innovation, Canadian Blood Services & Professor, University of Toronto

Dr. Barbara Hannach, Medical Officer, Medical Services and Utilization, Canadian Blood Services

Dr. Sophie Chargé, Associate Director, Centre for Innovation, Canadian Blood Services

Dr. Ed Pryzdial, Scientist, Centre for Innovation, Canadian Blood Services & Clinical Professor, University of British Columbia

Mr. Ahmed Coovadia, Hospital Liaison Specialist, Medical Services and Utilization, Canadian Blood Services

Miss Sue Gregoire, Senior Administrative Assistant, Centre for Innovation, Canadian Blood Services

Disclosure Declaration

This event received funding from the Canadian Blood Services Centre for Innovation.

Dr. Kathryn Webert, Dr. Sophie Chargé, Sue Gregoire, Dr. Walter Dzik, Dr. Barbara Hannach, Dr. William Sheffield, Dr. Robert Skeate, Dr. Donald Branch, Dr. Kathryn Webert, Ahmed Coovadia, Dr. Ed Pryzdial, and Karen Moffat have no actual or potential conflict of interest in relation to this program.

The following relationships that could be perceived as a related or apparent conflict of interest in the context of the subject of this program over the past FIVE (5) years are being disclosed by:

1/ Dr. Maureane Hoffman, Speaker, discloses:
   Grant/ Research Support: Name of Organization(s): 1) CSL Behring, 2) Boehringer Ingelheim, 3) Novo Nordisk
   Consultant: Name of Organization(s): 1) CSL Behring, 2) Novo Nordisk

2/ Dr. Alan Tinmouth, Speaker, discloses:
   Grant/ Research Support: Name of Organization(s): 1) Canadian Institutes for Health Research, 2) Canadian Blood Services
   Consultant: Name of Organization(s): 1) Canadian Blood Services, 2) Amgen, 3) GlaxoSmithKline, 4) Octapharma
3/ Dr. Mark Blostein, Speaker, discloses:
Grant/Research Support: Name of Organization(s): Bayer, Boehringer-Ingelheim
Consultant: Name of Organization(s): 1) Bayer, 2) Boehringer-Ingelheim, 3) BMS-Pfizer
Speakers' Bureau: Name of Organization(s): CSL-Behring

4/ Dr. Steve Pipe, Speaker, discloses:
Grant/Research Support: Name of Organization(s): 1) Pfizer, 2) Baxter
Consultant: Name of Organization(s): 1) Baxter, 2) CSL Behring, 3) Novo Nordisk, 4) Biogen Idec, 4) Pfizer, 5) Bayer

Providing Feedback & Receiving CME Accreditation

Following the event attendees will receive “a link” by email to complete an online evaluation questionnaire. We thank you for completing this evaluation as the information will be important to plan for future events.

Attendees will receive “a link” by email no later than three weeks after the end of the symposium for a personalized letter of CME accreditation. Please keep the email should you need to reprint the letter.

The mission of Canadian Blood Services is to operate Canada’s blood supply in a manner that gains the trust, commitment and confidence of all Canadians by providing a safe, secure, cost-effective, affordable and accessible supply of quality blood, blood products and their alternatives.

Through its Centre for Innovation, Canadian Blood Services facilitates the creation, translation and application of new knowledge to support a safe, effective and responsive system of blood and related biologics for Canada.